Current Report Filing (8-k)
August 14 2019 - 8:05AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): August 13, 2019
REGEN
BIOPHARMA, INC.
(Exact
name of small business issuer as specified in its charter)
Nevada
|
45-5192997
|
(State
or other jurisdiction of incorporation or organization)
|
(I.R.S.
Employer Identification No.)
|
Commission
File No. 333-191725
4700
Spring Street, St 304, La Mesa, California 91942
(Address
of Principal Executive Offices)
(619)
702 1404
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item
8.01 Other Events
On
August 13, 2019 Dr. Harry Lander requested that 5,000,000 common shares of KCL Therapeutics, Inc. (“KCL”) owned by
Dr. Lander be cancelled
The
abovementioned common shares were issued to Dr. Lander pursuant to a consulting agreement entered into on January 23, 2019 by
and between Dr. Lander and KCL.
Upon
effective cancellation of the 5,000,000 common shares owned by Dr. Lander, Regen Biopharma, Inc. will own 100% of KCL.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
REGEN
BIOPHARMA, INC.
|
|
|
Dated:
August 13, 2019
|
By:
/s/
David Koos
|
|
David
Koos
|
|
Chief
Executive Officer
|
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Regen Biopharma (PK) (USOTC:RGBPP)
Historical Stock Chart
From Sep 2023 to Sep 2024